Table 2.
Statistical data for the 38 probes (35 genes) that showed significant gene expression differences (main effects) for the cochlear samples of all the subject groups from the gene microarrays
| Probeset name | Symbol | P-value; F |
|---|---|---|
| Probeset up-regulated with age/hearing loss | ||
| Tumor necrosis factor receptor superfamily, member 12a | Tnfrsf12a | 0.001**; 8.33 |
| Tumor necrosis factor receptor superfamily, member 12a | Tnfrsf12a | 0.001**; 8.84 |
| Tumor necrosis factor superfamily, member 13b | Tnfsf13b | 0.036*; 3.73 |
| Rel oncogene | Rela | 0.035*; 3.78 |
| Nuclear factor of kappa light chain gene enhancer in B-cells inhibitor, alpha | Nfkbia | 0.002**; 7.92 |
| Nuclear factor of kappa light chain gene enhancer in B-cells inhibitor, beta | Nfkbib | 0.034*; 3.80 |
| CASP8 and FADD-like apoptosis regulator | Cflar/Cflip | 0.04*; 3.6 |
| CD40 antigen | Cd40 | 0.042*; 3.55 |
| Jun oncogene | Jun | 0.0125*; 5.12 |
| Mitogen activated protein kinase kinase kinase 1 | Map3k1 | 0.047*; 4.4 |
| Mitogen activated protein kinase kinase kinase 11 | Map3k11 | 0.028*; 4.05 |
| Dual specificity phosphatase 9 | Dusp9/Mkp4 | 0.042*; 3.56 |
| Activating transcription factor 3 | Atf3 | 0.0001***; 12.85 |
| C1q and tumor necrosis factor related protein 3 | C1qtnf3 | 0.024*; 4.25 |
| C1q and tumor necrosis factor related protein 5 | C1qtnf5 | 0.016*; 4.81 |
| Transformation related protein 53 | P53 | 0.014*; 4.97 |
| BH3 interacting domain, Harakiri, BCL2 interacting protein, apoptosis agonist | Hrk | 0.005**; 6.39 |
| B-cell leukemia/lymphoma 2 (Bcl2), transcript variant 1 | Bcl2 | 0.042*; 3.53 |
| B-cell leukemia/lymphoma 2 related protein A1d | Bcl2a1a | 0.001**; 8.83 |
| B-cell leukemia/lymphoma 2 related protein A1d | Bcl2a1a | < 0.0001***; 31.11 |
| Bcl2-like 1 | Bcl2l1 | 0.0135*; 5.01 |
| Bim/Bod/BCL2-like 11 (apoptosis facilitator), transcript variant 1 | Bcl2l11 | 0.016*; 4.80 |
| Bim/Bod/BCL2-like 11 (apoptosis facilitator), transcript variant 1 | Bcl2l11 | 0.043*; 3.52 |
| B-cell leukemia/lymphoma 3 | Bcl3 | 0.039*; 3.62 |
| Myeloid cell leukemia sequence 1 | Mcl1 | 0.033*; 3.84 |
| Caspase-1/IL-1B converting enzyme | Casp1 | 0.029*; 4.03 |
| Caspase-9 | Casp9 | 0.036*; 3.73 |
| Caspase 4/11, apoptosis-related cysteine protease | Casp4/11 | 0.008**; 5.70 |
| Apoptotic peptidase activating factor 1 | Apaf1 | 0.034*; 3.82 |
| Cytochrome c, somatic | Cycs | 0.018*; 4.61 |
| Probeset down-regulated with age/hearing loss | ||
| Tnf receptor-associated factor 3 | Traf3 | 0.03*; 3.96 |
| Mitogen activated protein kinase 10 | Mapk10 | 0.024*; 4.23 |
| Calpain 2 | Capn2 | 0.002**; 7.725 |
| Calpain 7 | Capn7 | 0.049*; 3.36 |
| Bcl2-like 2 | Bcl2l2 | 0.002**; 8.02 |
| B-cell CLL/lymphoma 7B | Bcl7b | 0.034*; 3.82 |
| Caspase 7 | Casp7 | 0.035*; 3.78 |
| Solute carrier family 25 (mitochondrial carrier, brain), member 14 | Slc25a14 | 0.009**; 5.6 |
F The F ratio for the main effects of the ANOVAs
*
0.01 < P < 0.05
**
0.001 < P < 0.01
***
0.0001 <P <0.001